IOL Chemicals & Pharmaceuticals secures China NMPA approval for Clopidogrel Bisulfate API

IOL Chemicals & Pharmaceuticals has received approval from the National Medical Products Administration (NMPA), China, for its Clopidogrel Bisulfate Active Pharmaceutical Ingredient (API). The Centre for Drug Evaluation (CDE) of the NMPA granted this approval on July 14, 2026. This regulatory clearance enables the company to expand its market access in China, adding to its existing valid Certificate of Suitability (CEP) for the same product.

Regulatory Approval Details

The approval from China's NMPA pertains to Clopidogrel Bisulfate, a widely used API in the formulation of antiplatelet medications. The following table summarizes the key details of this development:

Parameter	Details
Regulatory Body	China National Medical Products Administration (NMPA)
Product	Clopidogrel Bisulfate
Product Category	Active Pharmaceutical Ingredient (API)
Market	China
Approval Date	July 14, 2026

Significance of the Approval

Securing NMPA approval is a rigorous process that requires compliance with China's stringent pharmaceutical manufacturing and quality standards. This clearance allows IOL Chemicals & Pharmaceuticals to market and supply Clopidogrel Bisulfate API to pharmaceutical manufacturers operating within China. The development highlights the company's capability to meet international regulatory requirements across key global markets.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+6.29%	+11.05%	+13.12%	+111.37%	+60.76%	+23.50%

IOL Chemicals and Pharmaceuticals Limited reported a minor fire at its Minoxidil manufacturing unit, prompting a temporary suspension of operations at the facility. The incident occurred at approximately 9:50 p.m. on June 9, 2026, in Unit-9B at the company's manufacturing facility in Barnala, Punjab. While operations at the affected unit are expected to remain halted for 8–10 days, the company stated that other manufacturing units continue to operate normally and the overall impact is not expected to be significant.

Incident Overview

The fire was confined to Unit-9B, the Minoxidil manufacturing plant. No injuries were reported to any employee or personnel, and no significant damage to plant or property was caused. The company's site emergency response team promptly brought the incident under control in accordance with the established Onsite Emergency Management Plan. A detailed investigation is currently in progress to determine the root cause and identify corrective actions.

Parameter:	Details
Incident Type:	Minor fire
Affected Facility:	Unit-9B (Minoxidil Plant)
Location:	Village Fatehgarh Channa, Mansa Road, Barnala – 148101, Punjab
Operational Halt Duration:	8–10 days

Operational Impact

As a precautionary measure to facilitate inspection and restoration, operations at Unit-9B are temporarily suspended. The company's assets are adequately covered under insurance policies, and the extent of any insurable loss is being assessed. The disclosure was made to the National Stock Exchange of India and BSE Limited under Regulation 30 of the SEBI LODR Regulations.